Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
28.03
-0.36 (-1.27%)
Nov 2, 2026, 10:16 AM EST - Market open
Zenas BioPharma Employees
Zenas BioPharma had 167 employees as of December 31, 2025. The number of employees increased by 37 or 28.46% compared to the previous year. That makes Zenas BioPharma the 28,117th largest employer in the world and 3,550th in the United States.
Employees
167
Change (1Y)
37
Growth (1Y)
28.46%
Revenue / Employee
$5,988
Profits / Employee
-$2,900,503
Market Cap
1.83B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 167 | 37 | 28.46% |
| Dec 31, 2024 | 130 | 23 | 21.50% |
| Sep 30, 2024 | 115 | 31 | 36.90% |
| Jun 30, 2024 | 114 | 30 | 35.71% |
| Mar 31, 2024 | 107 | - | - |
| Sep 30, 2023 | 84 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Agios Pharmaceuticals | 540 |
| Intellia Therapeutics | 377 |
| Vir Biotechnology | 367 |
| Absci | 140 |
| Trevi Therapeutics | 34 |
| SELLAS Life Sciences Group | 13 |
ZBIO News
- 5 days ago - Citi adds ‘upside 90-day catalyst watch’ on Zenas BioPharma - TheFly
- 6 days ago - Zenas BioPharma Transcript: Investor update - Transcripts
- 6 days ago - Zenas BioPharma Slides: Investor update - Filings
- 16 days ago - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 20 days ago - Zenas BioPharma Slides: Corporate presentation - Filings
- 21 days ago - Zenas BioPharma presents new obexelimab data - TheFly
- 26 days ago - Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026 - GlobeNewsWire
- 27 days ago - Zenas BioPharma to Host Virtual R&D Event - GlobeNewsWire